Asset Details
Do you wish to reserve the book?
Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice
Do you wish to request the book?
Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice
2019
Overview
Ankylosing spondylitis is a chronic, progressive disease, and its treatment is relevant to the gut microbiota. Anti‐tumor necrosis factor‐alpha (anti‐TNF‐α) therapy alters the gut microbiota in many diseases, including inflammatory bowel disease. However, little is known about the effect of TNF‐α blocker treatment on the gut microbiota in ankylosing spondylitis. Herein, the effect of a TNF‐α blocker on the gut microbiota in proteoglycan‐induced arthritis was investigated. Proteoglycan‐induced mice were treated with an rhTNFR:Fc solution of etanercept (5 µg/g) for 4 weeks. rhTNFR:Fc treatment attenuated the arthritis incidence and severity of arthritis in the proteoglycan‐induced mice and decreased inflammation in the ankle joints and ameliorated ileal tissue destruction. Moreover, high gut permeability occurred, and zonula occludens‐1 and occludin protein levels were reduced in proteoglycan‐induced mice. These levels were significantly restored by the administration of rhTNFR:Fc. The serum TNF‐α and IL‐17 levels were also decreased. In addition, flora analysis via 16S rDNA high‐throughput sequencing revealed that rhTNFR:Fc treatment restored the gut microbiota composition to a composition similar to that in control mice. In conclusion, anti‐TNF‐α therapy attenuated proteoglycan‐induced arthritis progression and modulated the gut microbiota and intestinal barrier function. These results provide new insights for anti‐TNF‐α therapy strategies via regulating the gut microbiota in ankylosing spondylitis. Anti‐TNF alpha therapy attenuated the incidence and severity of ankylosing spondylitis in mice. Anti‐TNF alpha therapy modulated gut microbiota of ankylosing spondylitis in mice. Anti‐TNF alpha therapy repaired the gut barrier function of ankylosing spondylitis in mice.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
16S rDNA high‐throughput sequencing
/ Animals
/ Ankle
/ Antirheumatic Agents - pharmacology
/ Disease
/ Feces
/ Female
/ Gastrointestinal Microbiome - drug effects
/ Humans
/ Intestinal Mucosa - drug effects
/ Intestinal Mucosa - metabolism
/ Intestinal Mucosa - microbiology
/ Intestinal Mucosa - pathology
/ Mice
/ Original
/ Proteins
/ Proteoglycans - adverse effects
/ RNA, Ribosomal, 16S - genetics
/ rRNA 16S
/ Spondylitis, Ankylosing - diagnosis
/ Spondylitis, Ankylosing - drug therapy
/ Spondylitis, Ankylosing - etiology
/ Spondylitis, Ankylosing - metabolism
/ Therapy
/ Tight Junction Proteins - metabolism
